Experts discussed the benefits and challenges of implementing precision medicine protocols for oncology patients at this week's Tri-Conference meeting
The Dutch multinational is now on track to introduce a kitted version of the assay, which can be run on standard quantitative PCR equipment, by the end of the year.
By pulling in data from Higi health kiosks in retail pharmacies, Interpreta builds continuously updated care from genomics, clinical data, and patient lifestyles.
The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.
The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.
The model incorporates clinical, serological, and gene expression factors, and could be used to tailor treatment choices.
The Cambridge, Massachusetts-based precision medicine firm hopes to translate molecular information into therapies for chronic kidney diseases.
The model could shift which patients receive gene expression profiling assays but might not change the number of tests ordered.
The partners will also work together on a linked clinical genomic data set to guide future treatment decisions.
The Sanger Institute spin-off will use its sequencing and bioinformatics services to link genomic and clinical outcomes data for patient stratification.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.